SMARCA4-deficient Malignant Tumors clinical trials at UC Cancer

1 research study open to eligible people

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
open to eligible people ages 6 months to 40 years
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
at UCSF

Our lead scientists for SMARCA4-deficient Malignant Tumors research studies include Alyssa Reddy, MD.

Last updated: March 6, 2023

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers